uniQure NV (FRA:UQ1)
€ 14.66 0 (0%) Market Cap: 814.57 Mil Enterprise Value: 462.08 Mil PE Ratio: 0 PB Ratio: 15.15 GF Score: 65/100

uniQure N.V. - Special Call Transcript

Dec 21, 2020 / 01:30PM GMT
Release Date Price: €30.89 (-20.24%)
Maria E. Cantor
uniQure N.V. - Chief Communications Officer

Good morning, and thank you for joining us. This morning, uniQure announced that its hemophilia B gene therapy program has been placed on clinical hold by the U.S. Food and Drug Administration, pending review of a serious adverse event. This SAE is associated with the preliminary diagnosis of a form of liver cancer in one patient in the HOPE-B clinical trial being studied in adult patients with severe and moderately severe hemophilia B.

Joining me for this investor event and webcast are Mat Kapusta, our Chief Executive Officer; Dr. Ricardo Dolmetsch, our President of Research and Development; Eileen Sawyer, our Vice President of Global Medical Affairs; Dr. David Cooper, our Vice President of Clinical Development; Dr. Steven Pipe, Professor of Pediatrics and Pathology and the Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program at the University of Michigan and the Principal Investigator of the HOPE-B pivotal trial of EtranaDez; and Dr. Graham Foster, Professor of Hepatology at Queen Mary University in London

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot